Data as of .
GNOM vs IDNA: which is really different?
GNOM and IDNA hold 27% of their weight in the same names, and GNOM returned more over the year.
ETFIQ Off-Index Score: IDNA scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
27% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, GNOM and IDNA hold 27% of their money in the same securities at the same weight.
| Holding | GNOM | IDNA |
|---|---|---|
| MODERNA INC | 7.99% | 9.54% |
| TWIST BIOSCIENCE CORP | 7.40% | 7.09% |
| VERTEX PHARMACEUTICALS INC | 3.35% | 3.34% |
| CARIS LIFE SCIENCES INC | 2.72% | 3.39% |
| BIONTECH SE-ADR | 2.55% | 3.20% |
| CRISPR THERAPEUTICS AG | 2.89% | 1.50% |
| VIR BIOTECHNOLOGY INC | 0.92% | 1.30% |
| PERSONALIS INC | 0.85% | 0.94% |
| INTELLIA THERAPEUTICS INC | 1.03% | 0.47% |
| PACIFIC BIOSCIENCES OF CALIF | 0.28% | 0.36% |
| PRIME MEDICINE INC | 0.22% | 0.09% |
| Only in GNOM | Only in IDNA |
|---|---|
| 10X GENOMICS INC-CLASS A 6.53% | GENMAB 4.13% |
| GUARDANT HEALTH INC 5.78% | BAYER AG 3.87% |
| ILLUMINA INC 5.30% | REVOLUTION MEDICINES 3.76% |
| NATERA INC 5.13% | IOVANCE BIOTHERAPEUTICS INC 3.67% |
| GENSCRIPT BIOTECH CORP 4.29% | REGENERON PHARMACEUTICALS 3.63% |
| BIO-TECHNE CORP 3.56% | TAKEDA PHARMACEUTICAL 3.62% |
| BIOMARIN PHARMACEUTICAL INC 3.41% | INCYTE CORP 3.60% |
| QIAGEN N.V. 3.13% | MERCK & CO INC 3.57% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| GNOM | IDNA | GNOM | IDNA | GNOM | IDNA | |
| 3 months | +27.6% | +30.3% | +25.4 pts | +28.1 pts | +30.1 pts | +32.8 pts |
| 6 months | +56.4% | +41.4% | +38.4 pts | +23.4 pts | +32.2 pts | +17.2 pts |
| 1 year | +77.5% | +73.4% | +60.9 pts | +56.9 pts | +55.7 pts | +51.7 pts |
| 3 years | +59.3% | +91.3% | −19.1 pts | +12.9 pts | −38.9 pts | −6.9 pts |
| Since launch | +9.8% | +69.7% | −185.2 pts | −123.9 pts | −297.4 pts | −242.0 pts |
| GNOM Global X Genomics & Biotechnology ETF Holds 52 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies | IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Global X | iShares |
| Theme | Genomics and gene editing | Genomics and gene editing |
| In the S&P 500 | 20.9% | 23.9% |
| Active share vs the S&P 500 | 97.6% | 99.1% |
| In the Nasdaq-100 | 5.0% | 7.0% |
| Holdings | 52 | 62 |
| Top ten, share of the fund | 52.7% | 46.2% |
| Expense ratio | 0.50% | 0.47% |
| Fee for the differing part | 0.51% | 0.47% |
| Total return, 1 year | +77.5% | +73.4% |
| vs the S&P 500 | +60.9 pts | +56.9 pts |
| vs the Nasdaq-100 | +55.7 pts | +51.7 pts |
| Below its high | −39.6% | −24.7% |
| Net assets | $100m | $271m |
GNOM in plain words
By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 53% of the fund across 52 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +77.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 60.9 pts. It sits 39.6% below its all-time high of Feb 8, 2021.
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
Questions people ask
- Do GNOM and IDNA hold the same stocks?
- By their latest filings, 27% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, GNOM or IDNA?
- GNOM has 21% of its weight in S&P 500 names and IDNA has 24%, so IDNA differs more from the index.
- Which is cheaper, GNOM or IDNA?
- GNOM charges 0.50% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, GNOM against IDNA, data as of Sep 18, 2026. https://etfiq.com/compare/themes/gnom-vs-idna Free to use with attribution; the underlying files are at Open data.